AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

15,118.00p
   
  • Change Today:
    256.00p
  • 52 Week High: 15,316.00p
  • 52 Week Low: 10,022.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.98m
  • Volume: 2,861,517
  • Market Cap: £234,477m
  • RiskGrade: 123
  • Beta: 0.00

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 1.6% 0.0%
Div Cover 2.1 3.0
Op Mrgn 23.4% 32.2%
ROCE 58.0%  
Latest F'cast
P/E 31.2 20.4
PEG 0.7 n/a
Pr/Revenue 5.4 3.8
Pr/Book 6.5  
Latest F'cast
Revenue 8.6% -20.9%
PBT 42.7% 20.7%
EPS 45.4% 15.4%
DPS 3.2% -42.2%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,466.3 n/a -97% 287.00¢ 2.4%
31-Dec-22 44,351.00 2,501.00 212.00¢ 71.5 0.0 +2,550% 290.00¢ 1.9%
31-Dec-23 45,811.00 6,899.00 726.00¢ 19.7 0.1 +242% 290.00¢ 2.0%
31-Dec-24 54,073.00 8,691.00 454.00¢ 31.2 n/a -38% 310.00¢ 2.2%
31-Dec-25 58,739.00 12,402.00 660.00¢ 28.2 0.6 +45% 320.00¢ 1.7%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 62,769.11 20,239.83 761.46p 19.9 1.3 +15% 250.18p 0.0%
31-Dec-27 66,658.88 22,428.01 855.30p 17.7 1.4 +12% 261.63p 0.0%
31-Dec-28 70,666.24 24,305.88 939.65p 16.1 1.6 +10% 265.95p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Director/PDMR Shareholding 22-Dec-2025 11:00 RNS
Enhertu granted BTD for post-neoadjuvant early BC 22-Dec-2025 07:30 RNS
Update on LATIFY Phase III trial of ceralasertib 22-Dec-2025 07:00 RNS

AstraZeneca ShareCast News

AstraZeneca's COPD candidate succeeds in twin Ph... 27-Mar-2026 ShareCast
AstraZeneca's Calquence leukaemia treatment gets... 20-Feb-2026 ShareCast
Shore Capital lowers AstraZeneca to 'hold' 13-Feb-2026 ShareCast

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 15,118.00p
Change Today 256.00p
% Change 1.72 %
52 Week High 15,316.00p
52 Week Low 10,022.00p
Volume 2,861,517
Shares Issued 1,550.98m
Market Cap £234,477m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Income
68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 13
Neutral 3
Sell 0
Strong Sell 1
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 19-Feb-26 07-Aug-25
Paid 23-Mar-26 08-Sep-25
Amount 217.00¢ 103.00¢

Trades for 17-Apr-2026

Time Volume / Share Price
14:34 1 @ 14,966.00p
10:22 706,978 @ 14,736.00p
10:22 706,978 @ 14,736.00p
16:38 6 @ 15,118.00p
16:37 8 @ 15,118.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page